Date:6/27/2011

esistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs .For additional information on Chimerix, please visit http://www.chimerix.com.

'/>"/>

SOURCE Chimerix, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Chimerix to Present at Two Upcoming Investor Conferences
2. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
3. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
5. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
6. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Initiates Phase 1 Study of CMX157
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
11. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer